Boehringer’s deal spree; Prax­is’ li­cens­ing pact with Shang­hai biotech; Vi­co Ther­a­peu­tics rais­es $60M

Plus, news about PolyPid, Claram­e­tyx Bio­sciences, De­bio­pharm, Re­pare Ther­a­peu­tics, Im­mu­nic, Voy­ager Ther­a­peu­tics, Kymera Ther­a­peu­tics and Cat­a­lyst Phar­ma­ceu­ti­cals:

Boehringer In­gel­heim inks its third deal this week: The Ger­man biotech will pay up to €410 mil­lion in up­front and mile­stones to Ky­owa Kirin for world­wide rights to drugs for fi­bro-in­flam­ma­to­ry dis­eases. The deal fol­lows a can­cer im­munother­a­py tie-up and a liv­er dis­ease pact. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER